Evidence map›Paper›PMID 39001464›Full record

ArticleCancers2024

The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis.

John Yeakel, Steven N Seyedin, Garrett Harada, Garo Hagopian, Sharmeen Mahmood, Rebecca Bennett, Jeremy P Harris, Elliot M Abbott, Sydney Lindner, Farshid Dayyani and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

John YeakelDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
Steven N SeyedinDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0002-6841-968X
Garrett HaradaDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0002-7024-3783
Garo HagopianDepartment of Medicine, University of California Irvine, Orange, CA 92868, USA.
Sharmeen MahmoodDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
Rebecca BennettDivision of Vascular and Interventional Radiology, Department of Radiological Sciences, University of California Irvine, Orange, CA 92868, USA.
Jeremy P HarrisDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
Elliot M AbbottMIM Software Inc., Cleveland, OH 44122, USA.
Sydney LindnerMIM Software Inc., Cleveland, OH 44122, USA.
Farshid DayyaniDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0002-4970-5189
Varun SehgalDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
Jeffrey V KuoDepartment of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
Nadine Abi-JaoudehDivision of Vascular and Interventional Radiology, Department of Radiological Sciences, University of California Irvine, Orange, CA 92868, USA.ORCID 0000-0001-6163-8524

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Y-90 Selective Internal Radiotherapy (SIRT) is an ablative therapy used for inoperable liver metastasis. The purpose of this investigation was to examine the impact of local control after SIRT on overall survival (OS) in oligometastatic patients. A retrospective, single-institution study identified oligometastatic patients with ≤5 non-intracranial metastases receiving unilateral or bilateral lobar Y-90 SIRT from 2009 to 2021. The primary endpoint was OS defined from Y-90 SIRT completion to the date of death or last follow-up. Local failure was classified as a progressive disease at the target lesion(s) by RECIST v1.1 criteria starting at 3 months after SIRT. With a median follow-up of 15.7 months, 33 patients were identified who had a total of 79 oligometastatic lesions treated with SIRT, with the majority histology of colorectal adenocarcinoma (

Indexed as

liver metastaseslocal controloligometastaticOSSIRTY-90

Identifiers

PMID39001464
PMCPMC11240767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.